Upon careful examination of evidences presented by RephiLe Bioscience, the Patent Reexamination Board of the State Intellectual Property Office of China has made the decision to invalidate EMD Millipore patent ZL200480031805.7. This decision was made on July 3, 2015 to cancel all claims in this Millipore patent.
“RephiLe welcome the right judgment in this case.“ said Dr. Harry Yao, CEO of RephiLe Bioscience. “This decision reflects that in protecting intellectual properties, Chinese government and intellectual property management agencies treat multinational corporations the same way as small companies. This reexamination process reflected high professionalism shown by the Patent Reexamination Board and highly respects the facts and prior arts. This decision will help fair competition to the benefits of customers.”
RephiLe invest heavily in research every year to create highly innovative, high quality and valued products to the lab water users worldwide. This decision by the Patent Reexamination Board will further enhance RephiLe’s ability to provide high quality and affordable products to the end users worldwide.
Driven by innovation and quality, RephiLe is a dedicated provider of water purification systems and laboratory filtration products. RephiLe produces comprehensive and comparable consumables that can be used in Millipore lab water systems with reliable performance. It is RephiLe’s commitment to becoming a strategic partner for customers in the area of life science and biotechnology. The company is striving to bring superior quality, high value and innovative purification tools to enable and accelerate the advancement of the life sciences and technologies. Products are being sold to over 80 countries worldwide.